Breast Cancer Edition: Top Headlines for Week of September 5, 2022

In this episode, VTE rate with abemaciclib (uh-bem-uh-cy-clib) higher in real-world setting; Enhertu extends progression-free survival in patient subgroup; FDA grants priority review to elacestrant (ee-las-cess-trant) for metastatic disease; and more.

Read the full coverage here:

VTE rate with abemaciclib higher in real-world setting among patients with breast cancer

Enhertu extends progression-free survival in breast cancer subgroup, topline data show

FDA grants priority review to elacestrant for metastatic breast cancer

Lack of financial comfort linked to weight gain among young breast cancer survivors

Hispanic ethnicity often not reported in breast cancer studies

References:

Bazan JG, et al. JAMA Oncol. 2022;doi:10.1001/jamaoncol.2022.3527.

Press Release

Press Release

Sella T, et al. Cancer. 2022;doi:10.1002/cncr.34342.

Watson NW, et al. Cancer. 2022.doi:10.1002/cncr.34367.